Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives $17.33 Consensus PT from Analysts

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) have been assigned a consensus recommendation of “Moderate Buy” from the seven brokerages that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $17.3333.

A number of analysts have weighed in on the company. Wolfe Research raised Inventiva to a “strong-buy” rating in a research report on Thursday, November 6th. Canaccord Genuity Group restated a “buy” rating and set a $20.00 price target on shares of Inventiva in a research note on Tuesday, September 30th. Guggenheim decreased their price target on Inventiva from $13.00 to $11.00 and set a “buy” rating for the company in a report on Tuesday, November 18th. Wall Street Zen raised shares of Inventiva to a “hold” rating in a research note on Saturday, October 18th. Finally, HC Wainwright upped their price objective on shares of Inventiva from $20.00 to $24.00 and gave the stock a “buy” rating in a research report on Thursday, October 9th.

Inventiva Trading Up 2.4%

Shares of IVA opened at $4.76 on Tuesday. Inventiva has a fifty-two week low of $2.11 and a fifty-two week high of $7.98. The firm has a 50-day simple moving average of $4.34 and a 200-day simple moving average of $4.42.

Institutional Investors Weigh In On Inventiva

A number of hedge funds have recently added to or reduced their stakes in the company. Creative Planning purchased a new stake in Inventiva in the 2nd quarter valued at approximately $32,000. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Inventiva by 54.5% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 16,558 shares of the company’s stock valued at $50,000 after buying an additional 5,843 shares during the period. NewEdge Advisors LLC purchased a new stake in shares of Inventiva in the third quarter valued at approximately $116,000. Finally, Millennium Management LLC acquired a new position in Inventiva during the third quarter worth $649,000. Institutional investors and hedge funds own 19.06% of the company’s stock.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.